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Abstract
Purpose—Older cancer patients are at increased risk of cancer-related cognitive impairment. The 
purpose of this study was to assess the alterations in intrinsic brain activity associated with 
adjuvant chemotherapy in older women with breast cancer.
Methods—Chemotherapy treatment (CT) group included sixteen women aged ≥ 60 years (range 
60–82 years) with stage I-III breast cancers, who underwent both resting-state functional magnetic 
resonance imaging (rs-fMRI) and neuropsychological testing with NIH Toolbox for Cognition 
before adjuvant chemotherapy, at time point 1 (TP1), and again within 1 month after completing 
chemotherapy, at time point 2 (TP2). Fourteen age- and sex-matched healthy controls (HC) 
underwent the same assessments at matched intervals. Three voxel-wise rs-fMRI parameters: 
amplitude of low-frequency fluctuation (ALFF), fractional ALFF (fALFF), and regional 
homogeneity (ReHo), were computed at each time point. The changes in rs-fMRI parameters from 
TP1 to TP2 for each group, the group differences in changes (the CT group vs. the HC group), and 
the group difference in the baseline rs-fMRI parameters were assessed. In addition, correlative 
analysis between the rs-fMRI parameters and neuropsychological testing scores was also 
performed.
Results—In the CT group, one brain region, which included parts of the bilateral subcallosal gyri 
and right anterior cingulate gyrus, displayed increased ALFF from TP1 to TP2 (cluster p-
corrected=0.024); another brain region in the left precuneus displayed decreased fALFF from TP1 
to TP2 (cluster level p-corrected=0.025). No significant changes in the rs-fMRI parameters from 
TP1 to TP2 were observed in the HC group. Although ALFF and fALFF alterations were observed 
only in the CT group, none of the between-group differences in rs-fMRI parameter changes 
reached statistical significance.
Conclusions—Our study results of ALFF and fALFF alterations in the chemotherapy-treated 
women suggest that adjuvant chemotherapy may affect intrinsic brain activity in older women with 
breast cancer.
Background
Breast cancer is the most commonly diagnosed cancer in women, and almost half of new 
breast cancers are found in women over 60 years of age [1,2]. Older breast cancer patients 
are at increased risk of chemotherapy-associated toxicity, such as cancer-related cognitive 
impairment (CRCI) [3–5]. As the population ages and cancer treatment improves, increasing 
numbers of older cancer survivors are susceptible to CRCI. Cognitive problems present 
major challenges to patient care, as minor alterations in cognition can greatly affect 
independence [6]. However, the underlying mechanism of CRCI is not known, and even less 
is known about CRCI in older cancer survivors.
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Resting-state functional magnetic resonance imaging (rs-fMRI) is commonly used to assess 
the intrinsic brain activity that is associated with cognitive function [7–9]. Rs-fMRI uses 
blood oxygenation level-dependent (BOLD) contrast, which has been useful in studying 
CRCI [7–9]. Also, since rs-fMRI uses a shorter scanning time than task-based fMRI and the 
patients do not need to perform tasks during scanning, rs-fMRI is more tolerable for patients 
with cancer undergoing chemotherapy. Rs-fMRI allows assessment of intrinsic brain activity 
through three parameters: amplitude of low-frequency fluctuation (ALFF), fractional ALFF 
(fALFF), and regional homogeneity (ReHo). ALFF and fALFF analyze the intensity and 
power of regional spontaneous resting-state brain activity [10,11]. ReHo is a voxel-based 
measure of brain activity, which evaluates the synchronization between a given voxel and its 
neighboring voxels [12,13].
Rs-fMRI analysis for intrinsic brain activity has been used to evaluate and quantify 
physiological processes, such as cognitive training of young healthy adults [14], for 
evaluating the impact of pathological conditions, such as psychogenic erectile dysfunction 
[15], subcortical infarction [16] and brain glioma [17], and for evaluating the impact of 
cancer treatment [18,19]. One study of people with gastric cancer showed that decreased 
ALFF in the left frontal gyrus correlated with poor performance in executive function [18]. 
Another study used rs-fMRI to evaluate 19 women with breast cancer (mean age ± standard 
deviation [SD]: 43.1 ± 8.8 years) and found a chemotherapy-associated decline in memory 
performance and significant changes in activity in various brain regions [19]. However, 
limited data exists regarding intrinsic brain activity changes in older breast cancer female 
patients receiving adjuvant chemotherapy.
Here, we present the results from a prospective longitudinal study of women aged ≥ 60 years 
with stage I-III breast cancer receiving adjuvant chemotherapy. The study had the following 
objectives: 1) to assess the adjuvant chemotherapy-associated alterations in ALFF, fALFF, 
and ReHo, and 2) to explore the correlations between these rs-fMRI parameters and 
measures of cognitive performance, which were obtained through neuropsychological (NP) 
testing with NIH Toolbox for Cognition. We hypothesized that the three rs-fMRI parameters 
would be altered in one or more brain regions from pre- to post-chemotherapy in older 
women with breast cancer and that these changes would correlate with changes in cognitive 
performance.
Materials & Methods
Patients aged ≥ 60 years with stage I-III breast cancer with no history of neurological or 
psychiatric disorders or stroke were recruited prior to receiving adjuvant chemotherapy (CT 
group). Age- and sex-matched healthy controls without history of cancer or chemotherapy 
from the community with similar criteria but no cancer diagnosis were enrolled as healthy 
controls (HC group). The pre-chemotherapy assessment at baseline (time point 1, TP1), 
which included a brain MRI scan and NP testing with the NIH Toolbox for Cognition, was 
performed after surgery but before the start of adjuvant chemotherapy. The follow-up 
assessment (time point 2, TP2) was conducted within one month after the last infusion of 
chemotherapy. The HC group was tested with the same assessments at matched intervals. 
This prospective longitudinal study has been reported previously regarding brain volume, 
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gray matter density and subcortical brain iron [20–22] but not the rs-fMRI data reported 
here. This research protocol was approved by the Institutional Review Board at City of Hope 
National Medical Center. Written informed consent was obtained from all study participants.
Demographic and disease characteristics:
Demographic information for the study participants, including age, race, and education, was 
obtained through a self-report questionnaire. We obtained disease stage and treatment 
information, such as the chemotherapy regimen, through medical record abstraction.
Brain MRI scan acquisition:
All participants underwent brain MRI scans at both time points on the same 3T Verio 
Siemens scanner (Siemens, Erlangen, Germany) with a 12-channel head coil. The rs-fMRI 
data were acquired using rapid gradient echo-planar pulse imaging (EPI) with the following 
parameters: repetition time (TR) = 2000 millisecond (ms), echo time (TE) = 25 ms, field of 
view (FOV) = 224 × 224 mm2, voxel size = 3.5 × 3.5 × 3.5 mm3 and number of slices = 32 
(interleaved). From each participant, 160 volumes were acquired over 5 minutes and 20 
seconds. During data acquisition, the participants were instructed to keep their eyes closed 
without thinking about anything specific or falling into sleep. The anatomical imaging with 
the sagittal T1-weighted three-dimensional magnetization prepared rapid gradient echo 
(MPRAGE) sequence was also acquired.
Neuroimaging processing:
The first 10 volumes of each rs-fMRI acquisition were discarded for magnetization 
stabilization and the remaining 150 volumes were preprocessed using the Conn Toolbox [23] 
through the following six steps: 1) Slice-timing of the functional images was corrected using 
the middle slice as the reference. 2) Each volume in the functional image was aligned 
against the first volume through rigid body transformation. 3) The functional image was co-
registered to the anatomical image. 4) The anatomical images were spatially normalized to 
the Montreal Neurological Institute (MNI) space. 5) The co-registered functional images 
were spatially normalized and resampled to a voxel size of 2 × 2 × 2 mm3. 6) The time 
series in the functional images were de-noised through de-trending and linearly regressing 
out the head motion parameters.
Functions implemented in the “Resting-State fMRI Data Analysis Toolkit” were used to 
compute ALFF, fALFF and ReHo (normalized and de-noised) [24]. For ALFF and fALFF, 
the preprocessed images were smoothed (full width at half maximum [FWHM] = 6 mm) and 
the time series in each voxel was transformed into the frequency domain using fast Fourier 
transformation to obtain the power spectrum. ALFF was the average of the square root of the 
power spectrum over the frequency range of 0.01–0.08 Hz [10], while fALFF was the ratio 
between ALFF and the average square root of the power spectrum over the entire detectable 
frequency range [11]. ReHo images were obtained by voxel-wise calculation of Kendall’s 
coefficient of concordance (KCC) for the time series [12].
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All study participants were administered the NIH Toolbox Cognition Battery in a quiet area 
outside the MRI scanner [25]. The NIH Toolbox used a computerized format with national 
standardization and the Cognition Battery consists of seven measures to target subdomains 
of executive function, episodic memory, language, processing speed, working memory, and 
attention. This battery generated 10 scores (3 composite scores and 7 individual scores).
Statistical analysis:
Changes in the three rs-fMRI parameters (ALFF, fALFF and ReHo) between TP1 and TP2 
in the HC and CT groups, as well as the group differences in changes, were assessed using a 
mixed-design repeated-measures two-way analysis of variance (ANOVA) model in 
Statistical Parametric Mapping version12 (SPM12, Wellcome Trust Centre for 
Neuroimaging, London, UK). The model included a group factor (the HC group and the CT 
group), time factor (TP1 and TP2), and a subject factor to account for the subject effect in 
repeated measurements. The analysis was implemented using the flexible factorial design in 
SPM12. The design matrix contained columns for the four combinations of the group and 
time factors (HC*TP1, HC*TP2, CT*TP1, and CT*TP2) implementing the group by time 
interaction, along with the subject factor columns indicating the corresponding subject for 
each image. Various statistical hypotheses were tested by constructing appropriate contrasts. 
The weight vectors for the contrasts were constructed by setting the elements corresponding 
to the columns of the assessed variables to 1 or −1 and setting all other elements to zero. 
Uncorrected p < 0.001 was used as the threshold to locate potential statistically significant 
clusters.
Both voxel-wise linear regression analysis and region of interest (ROI)-based correlative 
analysis were performed to assess the relationship between the rs-fMRI parameters and the 
NP test scores. These analyses were confined within the regions where the CT group 
displayed statistically significant changes in rs-fMRI parameters over time. For each pair of 
rs-fMRI parameters and NP score, we assessed the following linear relationships between: 
1) two measures, i.e., the rs-fMRI parameters and the NP scores, at TP1; 2) the changes of 
these two measures from TP1 to TP2; and 3) the rs-fMRI parameters at TP1 and the change 
in NP score from TP1 to TP2. The total intracranial volume was used as a covariate in all 
analyses to control for its effects on the rs-fMRI parameters. ROI-based correlative analysis 
was performed by computing both the pair-wise Spearman (non-parametric) correlation and 
the associated p-values between the mean rs-fMRI values within the ROI and the ten NP 
scores. The statistical significance of the correlation was based on the p-values after adjusted 
for multiple comparison using the Bonferroni methods.
Results
Demographic data:
The detailed demographic characteristics of our study participants have been reported 
previously [20]. Briefly, 16 women with breast cancer (mean age ± SD: 67.0 ± 5.39 years) 
and 14 age- and sex-matched healthy controls (mean age ± SD: 67.8 ± 5.24 years) 
underwent study assessments at two time points. There were no statistically significant 
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differences in age or overall education between the two groups (p > 0.05). The CT group 
included 11 (68.8%) white and 5 (31.2%) black females, and the HC group included 14 
(100%) white females (p = 0.04). The breast cancer staging of the participants was as 
follows: 5 (31.3%) with stage I, 8 (50.0%) with stage II, and 3 (18.7%) with stage III. In the 
CT group, 7 (43.8%) received docetaxel and cyclophosphamide (TC regimen) and 9 (56.2%) 
received a chemotherapy regimen other than TC.
Within-group changes of rs-fMRI parameters from TP1 to TP2:
The CT group displayed a statistically significant increase in ALFF from TP1 to TP2 in a 
single cluster that included parts of the bilateral subcallosal gyri and right anterior cingulate 
gyrus (BA 32) (cluster p-corrected = 0.024, Table 1 and Figure 1). The CT group also 
displayed a statistically significant decrease in fALFF from TP1 to TP2 in a single cluster in 
the left precuneus (cluster p-corrected = 0.025, Table 1 and Figure 2). The spatial 
distribution of the cluster regarding the fALFF alteration in Figure 2 extended to the right 
precuneus. However, the cluster was only statistically significant at the left precuneus 
(cluster p-corrected = 0.025).
There were no changes from TP1 to TP2 for ReHo in the CT group (p-corrected > 0.05). 
The HC group did not show any statistically significant changes from TP1 to TP2 for any of 
the rsfMRI parameters (p-corrected > 0.05).
Between-group comparison of rs-fMRI parameters:
There were no between-group differences (the CT group vs. the HC group) for any of the 
three rs-fMRI parameters at TP1 or TP2 (p-corrected > 0.05). No between-group differences 
were noted when comparing the changes from TP1 to TP2 in the CT group to that in the HC 
group for each of the three rs-fMRI parameters (p-corrected > 0.05).
Correlations between rs-fMRI parameters and NP scores:
No statistically significant between-group differences (the CT group vs. the HC group) for 
any of the ten NP test scores were noted at TP1 or from TP1 to TP2, which has been 
reported previously [20]. Here, voxel-wise linear regression analysis did not identify an 
association of ALFF or fALFF with any of the ten NP scores within the two clusters 
involving subcallosal gyri and right anterior cingulate gyrus, and left precuneus where the 
CT group displayed significant changes from TP1 to TP2 (p-corrected > 0.05). ROI-based 
correlative analysis identified positive correlation between the change in ALFF and the 
change in the testing scores for Pattern Comparison Processing Speed from TP1 to TP2 in 
the HC group (r = 0.84, p = 0.0002) (Figure 3), but not in the CT group (r = −0.19, p = 0.47).
Discussion
To the best of our knowledge, the current study is the first prospective longitudinal study of 
brain intrinsic activity in older women with breast cancer undergoing adjuvant 
chemotherapy. In the breast cancer patients treated with chemotherapy, we observed changes 
from TP1 to TP2 in two intrinsic brain activity parameters: increased ALFF in the bilateral 
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subcallosal gyrus and right anterior cingulate cortex and decreased fALFF in the left 
precuneus. However, no such changes were observed in the healthy controls.
The anterior cingulate cortex, as part of the frontal lobe, regulates fundamental cognitive 
process such as motivation, decision-making, and learning [26,27]. Important cognitive 
functions in the frontal lobe, such as executive function, memory and language, are 
vulnerable to chemotherapy-associated structural and functional alterations [8,20,28,29]. For 
instance, a longitudinal study by McDonald and colleagues studying a similar number of 
chemotherapy patients in a younger age group at around 50 years of age showed an acute 
reduction in frontal lobe gray matter density one month after completion of chemotherapy 
[30]. They also showed that decreased frontal gray matter density was accompanied by self-
reported difficulties in executive functioning. Additional longitudinal brain structural MRI 
studies support a similar pattern of frontal gray matter alterations [31,32]. In our current 
cohort, we previously observed reduced frontal lobe volume in the CT group from TP1 to 
TP2 [20] and reduced gray matter density mostly in the frontal lobes, including the bilateral 
inferior frontal gyri, bilateral insula, left anterior cingulate gyrus, left inferior frontal gyrus 
(BA 47), and right middle frontal gyrus [21]. In this analysis, we observed altered frontal 
lobe intrinsic brain activity in the frontal lobe in the CT group. Our findings provide 
additional evidence that the frontal lobe is susceptible to chemotherapy-associated 
alterations in cancer patients, including older patients.
We also identified a chemotherapy-associated decrease in fALFF in the precuneus brain 
region in the CT group. The precuneus is in the medial aspect of the parietal lobe; this region 
is part of the association cortices, which shares connections with other cortical and 
subcortical regions [33]. In addition, the precuneus is a functional core of the default-mode 
network (DMN) which supports learning, autobiographical memory, creativity, etc. and is 
sensitive to chemotherapy toxicity and vulnerable to aging [34–36,8]. The DMN includes 
the precuneus, posterior cingulate, medial frontal, middle temporal and lateral parietal 
regions and hippocampus, and it is the one of the most commonly observed resting-state 
brain networks [35]. Reduced DMN connectivity is a potential neuroimaging biomarker of 
age-and disease-related cognitive decline [35]. Kesler and colleagues showed that DMN 
resting-state functional connectivity patterns could be used to discriminate chemotherapy-
treated from no-chemotherapy-treated breast cancer survivors or from healthy controls [36]. 
Another study from the same group showed disrupted organization of the global resting-state 
functional brain network following chemotherapy in breast cancer survivors [8]. Their study 
showed the nodal degree and number of hubs were decreased in the orbitofrontal, 
dorsolateral prefrontal and middle temporal regions, indicating altered functional network 
topology. Our current study did not directly examine DMN functional connectivity. Instead, 
we used data-driven methods to evaluate intrinsic brain activation patterns in the whole brain 
without the need to specify a hypothesis-driven ROI [10–13]. Our finding of decreased 
fALFF in the precuneus is consistent with the literature regarding the disrupted DMN 
functional brain connectivity involving the precuneus following chemotherapy [35,36]. Our 
study results again implicate the precuneus as a critical brain region for chemotherapy-
associated brain alterations.
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The increased ALFF in the subcallosal gyri and right anterior cingulate gyrus coupled with 
decreased fALFF in the left precuneus were in general agreement of compensatory efforts 
described in literature [9]. We speculate that brain activity may increase in one region to 
compensate for decreased activity in another region. This may help the patients to maintain 
cognitive function. Such a compensatory mechanism may also explain why we observed no 
chemotherapy-associated changes in the NP test scores. Neuroplasticity and compensation 
have been postulated to underlie the relationship between cancer and cognition [9,37]. A 
study by Cimprich and colleagues showed that cancer patients had increased brain activation 
by recruiting additional neurocircuitry during a high-memory task load before chemotherapy 
compared to healthy controls [37]. Their study provided evidence that patients used 
compensatory efforts to achieve similar cognitive testing scores as the controls. We postulate 
that the older cancer patients in our study cohort may have also used compensatory efforts; 
however, further work is needed to test this hypothesis. In addition, we acknowledge that the 
small sample size of this study may not provide sufficient power to identify subtle changes 
in cognitive performance.
In order to identify the potential correlation of chemotherapy-associated brain changes 
between intrinsic brain activity and gray matter density, we co-registered the coordinates of 
ALFF and fALFF alterations with the coordinates of the clusters showing the gray matter 
density reduction [21]. We found no overlap of specific brain regions. We speculate that 
chemotherapy may have affected brain structure and intrinsic brain activity differently, thus 
resulting in alterations in different brain regions.
We found no significant alterations in the ReHo values after chemotherapy. This is in 
contrast to prior work showing a chemotherapy-associated decrease in the ReHo values in 
the frontal lobe such as the right orbitofrontal area and left dorsolateral prefrontal cortex in 
19 younger Asian breast cancer patients (mean age ± SD: 43.1 ± 8.8 years) [19]. ReHo is a 
voxel-based measure of brain activity, which evaluates temporal similarity of a given voxel 
to its neighbors [12,13] and it has been used to identify alterations in intrinsic brain activity. 
We speculate that the small sample size of this study, older study participants, potential 
compensatory efforts in the CT group and short-term follow-up may have limited our ability 
to detect subtle changes in the ReHo values.
We found a correlation between increased ALFF and improved Pattern Recognition 
Processing Speed scores in the HC group but not in the CT group. Our study findings are 
divergent from previous reports. Processing speed serves as the foundation for other 
cognitive process, including working memory, attention, executive function, and memory 
[38]. Kvale and colleagues reported that chemotherapy exposure in older patients was 
associated with decreased processing speed [39]. In addition, Lepage and colleagues 
observed a significant correlation between gray matter reduction in the left insular cortex 
and processing speed in chemotherapy-treated cancer patients [32]. There are several 
possible explanations for the discrepancy between our study and the prior work. First, our 
study participants (ranging from 60 to 82 years) were generally older than the participants in 
the reported studies, and aging may influence the cognitive response to chemotherapy. 
Second, the focus of our study was different from the prior studies (31, 38). Our study 
focused on brain intrinsic activity data obtained from rs-fMRI while prior studies focused on 
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cognitive testing data [39] or brain structural data such gray matter changes in 
chemotherapy-treated patients [32]. Third, the lack of correlation in our CT group might be 
partially due to a chemotherapy-associated decrease in the practice effect from repeated 
administration of cognitive tests, whereas the HC participants may derive more benefit from 
practice [40].
Our study result showed that the significant correlation between ALFF and Processing 
Speed scores in the HC group seemingly relied on two control individuals who had worse 
performance overtime (Figure 3). We speculate that our controls were older adults who 
might be more susceptible to cognitive changes due to aging and co-morbidities. 
Nevertheless, there was no statistically significant change in the testing scores at the group 
level. Our study finding may serve as pilot data for generating hypothesis for a future study 
of CRCI in older patients.
There are several limitations in this study. The short follow-up duration, small sample size, 
heterogeneous stages and chemotherapy regimens could contribute to the non-significant 
correlation between rs-fMRI and NP scores in the chemotherapy group. In addition, we were 
limited by a lack of breast cancer control group without chemotherapy to evaluate the effect 
of the cancer on brain activity and cognition. Despite the limitations, there were strengths; 
this study used data-driven methods to assess intrinsic brain activity patterns in the entire 
brain and evaluated these patterns as candidate neuroanatomical correlates of cognitive 
function. Our study focusing on older breast cancer patients undergoing adjuvant 
chemotherapy contributes much needed information about brain structure and function in the 
population of older cancer patients, who are potentially more susceptible to cognitive issues 
from aging.
In summary, we observed a chemotherapy-associated increase in ALFF in bilateral 
subcallosal gyri and right anterior cingulate gyrus and a decrease in fALFF in left precuneus 
in older breast cancer patients. We also found a significant correlation between increased 
ALFF values and cognitive processing speed in older adults with no history of cancer. Our 
study results support the notion that intrinsic brain activity parameters may serve as 
neuroimaging biomarkers for cognitive functioning in older patients with cancer undergoing 
adjuvant chemotherapy. Future studies with a larger cohort and longer follow-up are needed 
to validate these findings.
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Alterations in the amplitude of low-frequency fluctuation (ALFF) in the chemotherapy 
group from pre- (time point 1, TP1) to post-chemotherapy (time point 2, TP2). The 
highlighted area is a single cluster showing a statistically significant increase in ALFF from 
TP1 to TP2 (p-corrected < 0.05). This cluster includes parts of the right subcallosal gyrus (8, 
16, −16), left subcallosal gyrus (−8, 14, −14) and right anterior cingulate gyrus (4, 22, −8; 
Brodmann 32). The color bar in the right lower panel indicates the scale of the t statistics for 
the within-group comparison of ALFF between the TP1 and TP2.
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Alteration of fractional amplitude of low-frequency fluctuation (fALFF) in the 
chemotherapy group from pre- (time point 1, TP1) to post-chemotherapy (time point 2, 
TP2). One cluster (indicated in yellow) in the left precuneus (0, −56, 44) shows a 
statistically significant decrease in fALFF from TP1 to TP2 (p-corrected < 0.05). The blue 
crosshair indicates the cluster peak (0, −56, 44) in each plane. The color bar in the right 
lower panel indicates the scale of the t statistics for the within-group comparison of fALFF 
between TP1 and TP2.
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Spearman correlation and the associated p-values between the changes in ALFF and changes 
in Pattern Comparison Processing Speed test scores from pre- to post-chemotherapy for the 
chemotherapy (CT) group (left) and the healthy control (HC) group (right). Linear 
regression was performed to obtain the fitting curve.
Note: pat_compare_proc: Pattern Comparison Processing Speed
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Table 1
Statistically significant alterations in rs-fMRI parameters from TP1 to TP2 in the chemotherapy group
rs-fMRI comparison x,y,z (mm) cluster size cluster p (corr) voxel p (FWE) voxel p (FDR) voxel T Region
ALFF CT: TP2 > 
TP1
8, 16, −16 75 0.024 0.568 0.559 5.35 R Subcallosal Gyrus
−8, 14, −14 75 0.024 0.76 0.559 5.10 L Subcallosal Gyrus
4, 22, −8 75 0.024 1 0.559 4.26 R Anterior 
Cingulate (BA 32)
fALFF CT: TP2 < 
TP1
0, −56, 44 46 0.025 0.733 0.548 5.40 L Precuneus
MRI magnetic resonance imaging, rs-fMRI resting-state functional MRI, ALFF amplitude of low-frequency fluctuation, fALFF fractional ALFF, 
CT chemotherapy group, TP1 time point 1 (prior to chemotherapy), TP2 time point 2 (after chemotherapy), FWE family-wise error rate, FDR false 
discovery rate, L left, R right, BA Brodmann area, corr correlation.
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